US12410183B2ActiveUtilityPatentIndex 60
Sars-cov2 main protease inhibitors
Est. expiryAug 5, 2042(~16.1 yrs left)· nominal 20-yr term from priority
Inventors:AMMANN STEPHEN ECAI XINPEICANALES EDA YCHANG WENG KCHIN GREGORY FKINFE HENOK HLAZERWITH SCOTT EMCKINLEY JESSICA LMISH MICHAEL RNADUTHAMBI DEVANPERRY JASON KRODRIGUEZ KEVIN XSCHROEDER SCOTT DSWANK CHRISTOPHER JVAN VELDHUIZEN JOSHUA J
C07D 513/04C07D 498/04C07D 491/113C07D 491/107C07D 487/10C07D 487/04C07D 471/04C07D 417/14C07D 413/14C07D 409/14C07D 405/14C07D 401/14A61P 31/14C07D 519/00C07D 401/04C07D 491/052C07D 495/10C07D 491/08A61P 31/12A61K 31/517A61K 31/519C07D 471/10C07D 495/04
60
PatentIndex Score
1
Cited by
89
References
25
Claims
Abstract
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a compound selected from
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the viral infection is a coronavirus infection.
15. The method of claim 4 , wherein the viral infection is a coronavirus infection.
16. The method of claim 5 , wherein the viral infection is a coronavirus infection.
17. The method of claim 11 , wherein the viral infection is a coronavirus infection.
18. The method of claim 1 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2.
19. The method of claim 4 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2.
20. The method of claim 5 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2.
21. The method of claim 11 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2.
22. The method of claim 1 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).
23. The method of claim 4 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).
24. The method of claim 5 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).
25. The method of claim 11 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.